Table 1. Baseline characteristics.
| Characteristics | Patients receiving CBD (n = 44) | |
|---|---|---|
| Male:female | 28 (63.6):16 (36.4) | |
| Mean age, yr | 5.1 (max = 15.8, min = 1.2, IQR = 2.9–6.5) | |
| Epilepsy syndrome | ||
| Lennox-Gastaut syndrome | 34 (77.3) | |
| Dravet syndrome | 10 (23.3) | |
| Concomitant use of antiepileptic drugs | 3 (1–5) | |
| Antiepileptic drugs used | ||
| Valproic acid | 36 (81.8) | |
| Clobazam | 17 (38.6) | |
| Topiramate | 12 (27.3) | |
| Stiripentol | 5 (11.4) | |
| Other treatment in progress at the time of CBD use | ||
| Diet therapya | 5 (11.4) | |
| Steroidsb | 2 (4.5) | |
| EEG patterns before cannabidiol treatment | ||
| Paroxysmal fast activities | 16 (36.3) | |
| Generalized sharp and slow waves | 17 (38.6) | |
| Abnormal brain MRI findings | 22 (50) | |
Data are presented as median (range) or number (%) unless otherwise indicated.
CBD = cannabidiol, IQR = interquartile range, EEG = electroencephalogram, MRI = magnetic resonance imaging.
aAll diet therapies used in this study were the modified Atkins diet; bAll used deflazacort.